The respiratory medicine specialist said the objective is to dose patients with the treatment earlier in the infection cycle before severe lower respiratory tract symptoms develop.
READ: Synairgen jumps as SNG001 trial on coronavirus patients labelled as an Urgent Public Health study
Meanwhile, the company said the current trial of SNG001 for patients in hospital settings was “progressing well” with more than 75 patients dosed out of the target of 100. Results from this study are expected in June.
The expansion of the trial follows news earlier this month that the trial of SNG001 had been classified as an Urgent Public Health study by the National Institute for Health Research.
Today's news sent the shares up 18.2% to 61.4p in lunchtime trading.